Tarsus Pharmaceuticals, Inc. (NasdaqGS: TARS)
Health Care · Pharmaceuticals · US
$75.77
+3.57% today · +4.0% 1Y
Tarsus Pharmaceuticals, Inc. (NasdaqGS: TARS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.21B and employs 370 people.
Over the last twelve months the share price has gained 4.0%, trading between 53.89 and 91.53.
Tweenvest scores Tarsus Pharmaceuticals, Inc. across four factors: quality 48/100, value 64/100. Its strongest factor is value.
TARS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.21B
- Revenue (TTM)
- $606.33M
- P/E
- —
- EPS
- -1.08
- Dividend yield
- —
- Beta (5Y)
- 0.45
- 52-week high
- $91.53
- 52-week low
- $53.89
- Avg volume (3M)
- —
- Shares outstanding
- 43.88M
- Employees
- 370
- Next earnings
- —
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
- ISIN
- US87650L1035
- Founded
- 2016
- Listed since
- Oct 16, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Laboratorios Farmaceuticos Rovi, S.A.BME: ROVI | $3.32B | €58.75 | +1.21% |
| Jiangsu Nhwa Pharmaceutical Co., LTDSZSE: 002262 | $3.30B | CN¥21.74 | -4.36% |
| China Medical System Holdings LimitedSEHK: 867 | $3.27B | HK$10.54 | +0.96% |
| Guangdong Zhongsheng Pharmaceutical Co., Ltd.SZSE: 002317 | $3.23B | CN¥25.49 | +6.08% |
| Tasly Pharmaceutical Group Co., LtdSHSE: 600535 | $3.17B | CN¥14.20 | +1.43% |
| Hybio Pharmaceutical Co., Ltd.SZSE: 300199 | $3.13B | CN¥23.71 | -0.88% |
| Evopoint Biosciences Co., Ltd.SHSE: 688837 | $3.07B | CN¥47.25 | -4.35% |
| Jilin Aodong Pharmaceutical Group Co., Ltd.SZSE: 000623 | $3.07B | CN¥17.53 | +0.69% |
Figures last refreshed Oct 11, 2026.